Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The pathogenesis and treatment of hemolytic uremic syndrome.

Literature DB >> 9621299

The pathogenesis and treatment of hemolytic uremic syndrome.

B S Kaplan¹, K E Meyers, S L Schulman.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1998 PMID： 9621299 DOI： 10.1681/ASN.V961126

Source DB: PubMed Journal: J Am Soc Nephrol ISSN： 1046-6673 Impact factor: 10.121

Keyword Cloud
Cited

× No keyword cloud information.

38 in total

1. New approach to treating Escherichia coli O157:H7?

Authors: P Beaupré
Journal: Can Fam Physician Date: 2000-07 Impact factor: 3.275

2. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors: Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal: Blood Date: 2006-04-18 Impact factor: 22.113

3. Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome.

Authors: Emily Elizabeth Bowen; Robert Hangartner; Iain Macdougall
Journal: J Gen Intern Med Date: 2015-05-23 Impact factor: 5.128

4. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Authors: Fadila Guessous; Marek Marcinkiewicz; Renata Polanowska-Grabowska; Sudawadee Kongkhum; Daniel Heatherly; Tom Obrig; Adrian R L Gear
Journal: Infect Immun Date: 2005-12 Impact factor: 3.441

10. Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease.

Authors: Matthew A Geramita; Johannes Hofer; James Cooper; Michael L Moritz
Journal: BMJ Case Rep Date: 2017-08-30

The pathogenesis and treatment of hemolytic uremic syndrome.

1. New approach to treating Escherichia coli O157:H7?

2. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

3. Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome.

4. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

5. Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection.

Review 6. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

7. Characteristics and outcome of hemolytic uremic syndrome in Sudanese children in a single Centre in Khartoum State.

8. Idiopathic Atypical Hemolytic Uremic Syndrome (aHUS) with Trilineage Myelodysplasia.

9. Invasive Streptococcus pneumoniae infection causing hemolytic uremic syndrome in children: Two recent cases.

10. Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease.